Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Gains from Investment Securities: 2009-2024

Historic Gains from Investment Securities for Ligand Pharmaceuticals (LGND) over the last 16 years, with Dec 2024 value amounting to $5.1 million.

  • Ligand Pharmaceuticals' Gains from Investment Securities rose 75.20% to $219,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $11.2 million, marking a year-over-year increase of 214.24%. This contributed to the annual value of $5.1 million for FY2024, which is 12.95% up from last year.
  • Per Ligand Pharmaceuticals' latest filing, its Gains from Investment Securities stood at $5.1 million for FY2024, which was up 12.95% from $4.5 million recorded in FY2023.
  • Ligand Pharmaceuticals' Gains from Investment Securities' 5-year high stood at $9.5 million during FY2020, with a 5-year trough of $4.5 million in FY2023.
  • Its 3-year average for Gains from Investment Securities is $6.0 million, with a median of $5.1 million in 2024.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first plummeted by 98.83% in 2020, then climbed by 12.95% in 2024.
  • Ligand Pharmaceuticals' Gains from Investment Securities (Yearly) stood at $9.5 million in 2020, then declined by 3.78% to $9.2 million in 2021, then decreased by 10.36% to $8.2 million in 2022, then crashed by 44.79% to $4.5 million in 2023, then climbed by 12.95% to $5.1 million in 2024.